Table 1.
Studies on ablation therapy for liver metastasis from mixed types of primary tumors
| Author | Publication year | Type of primary tumor | Type of ablation | No. of patients | Size of tumors [mm] | Follow-up [months] | Local tumor control [%] | Overall survival [months] | Overall survival [%] (Progression-free survival[%]) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-year | 2-year | 3-year | 4-year | 5-year | |||||||||
| Vogl et al. [4] | 2022 | CRC, breast, pancreas, etc | MWA | 26 | 17.2 (mean) | 24 | 100 | – | 84.6 | 76.9 | – | – | – |
| RFA | 24 | 15.3 (mean) | 91.7 | – | 87.5 | 62.5 | – | – | – | ||||
| Liu et al. [5] | 2014 | GI, kidney, lung, etc | RFA | 22 | – | – | 90.9 | – | 73.9 | – | 45.4 | – | 37.5 |
| Wu et al. [6] | 2013 | CRC, breast, stomach, etc | RFA | 136 (CEUS group) | 32 (mean) | 16.3 | 83 | 38 | 82.5 | 64.3 |
50.1 (38.3) |
– | – |
| 126 (control group) | 34 (mean) | 21.9 | 70.6 | 20 | 73.5 | 44.9 |
25.3 (19.3) |
– | – | ||||
RFA radiofrequency ablation, MWA microwave ablation, CRC colorectal cancer, GI gastrointestinal